By |

Profile

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes RELVAR/BREO/ELLIPTA, ANORO, ELLIPTA, TRELEGY, ELLIPTA, and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Contact Information

Website: www.inva.com
Email: investor.relations@theravance.com
Main Phone: +1 650 238-9600
Address: 2000 Sierra Point Parkway
Address 2: Suite 500
State: CA
City / Town: Brisbane
Country: USA
Postal Code: 94005

Issuer Information

Exchange: NGS
CEO: Eric d'Esparbes
Employees: 6
NAICS: Pharmaceutical Preparation Manufacturing(325412)


Gathering Data... Please wait

Profile

Innoviva Inc develops biopharmaceutical drugs in the antibiotic, respiratory, and digestive realms. Theravance's respiratory compounds are in late-stage trials for asthma and chronic obstructive pulmonary disease. Its product offering includes RELVAR/BREO/ELLIPTA, ANORO, ELLIPTA, TRELEGY, ELLIPTA, and others. The firm collaborates with and receives funding from GlaxoSmithKline.

Contact Information

Website: www.inva.com
Email: investor.relations@theravance.com
Main Phone: +1 650 238-9600
Address: 2000 Sierra Point Parkway
Address 2: Suite 500
State: CA
City / Town: Brisbane
Country: USA
Postal Code: 94005

Issuer Information

Exchange: NGS
CEO: Eric d'Esparbes
Employees: 6
NAICS: Pharmaceutical Preparation Manufacturing(325412)
$ 19.47 $ 0.04 (0.21%)
Last Price 19.47 Change $ 0.04 Change % 0.21 Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open 19.39 High 19.66 Low 19.27 Prev Close 19.43
Last Trade Volume 673,608 52 Wk Hi 19.82 52 Wk Low 13.26
Market Cap 2 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 101,039,707.00 EPS (TTM) 1.69 PE Ratio 11.50 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 18
Number of Buys 0 2
Number of Sells 0 16
Net Activity 0 -117433
Last 10 Buys Shares
N/A 0
Last 10 Sell Shares
Michael W. Aguiar 1,000
Theodore L. Witek 1,000
George B. Abercrombie 1,000
Eric d'Esparbes 1,000
Eric d'Esparbes 1,000
Eric d'Esparbes 1,000
Eric d'Esparbes 1,000
Theodore L. Witek 1,000
Eric d'Esparbes 1,000
Theodore L. Witek 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 16 16 16 16
Low Target Price Estimate 8 8 8 8
Mean Target Price Estimate 12.75 12.75 12.8 12.75
Standard Deviation 3.4 3.4 2.95 3.4
Date of Most Recent Estimate 05/11/18 05/11/18 05/11/18 05/11/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 0 0 0 0
Moderate Buy 0 0 0 0
Hold 2 3 3 3
Moderate Sell 1 1 1 1
Strong Sell 1 1 1 1
Mean Rec. 3.58 3.46 3.46 3.46